A Study on Effect of Melatonin in Dyslipidemia Caused by Experimentally Diabetes

Abstract

In this study, it was aimed to determine the effects of melatonin application on lipid profile in streptozotocin-induced diabetic rats. Animals in control group were not any treatment. Melatonin group animals received 50 mg/kg melatonin intraperitoneally in daily for eight weeks. Diabetes was induced by subcutaneous injections of streptozotocin at dose of 40 mg/kg for two days as a single dose per day in diabetes group animals. Animals in Diabetes+Melatonin group were made diabetic by streptozotocin in the same way and then these animals received 50 mg/kg melatonin intraperitoneally in daily for eight weeks. In blood samples taken from all animals, TNF-α, triglyceride, total cholesterol, LDL and HDL were determined. In diabetes group, TNF-α level were high (p<0.05). The changes in TNF-α level with melatonin application to diabetic rats were important (p<0.05). In diabetic rats, triglyceride and LDL levels were found to be enhanced compared to control group (p<0.05), HDL level was significantly low (p<0.05), while the change in total cholesterol level was not important. With the melatonin application to diabetic rats, HDL level was found to be higher (p<0.05) and LDL level was lower than diabetes group (p<0.05). It was concluded that the administration of melatonin to streptozotocin-induced diabetic rats may have positive effects on lipid profile.

Keywords

• Diabetes,melatonin,TNF-α,lipid profile

References

1. 1. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol, 2001; 11(9): 372-377.
2. 2. Chan TY, Tang PL. Effect of melatonin on the maintenance of cholesterol homeostasis in the rat. Endocr Res, 1995; 21(3): 681-696.
3. 3. Chang CL, Lin Y, Bartolome AP, Chen YC, Chiu SC, Yang WC. Herbal therapies for type 2 diabetes mellitus: Chemistry, biology, and potential application of selected plants and compounds. Evid Based Complement Alternat Med, 2013; 2013: 378657.
4. 4. Chen J, Mangelinckx S, Adams A, Wang ZT, Li WL, De Kimpe N. Natural flavonoids as potential herbal medication for the treatment of diabetes mellitus and its complications. Nat Prod Commun, 2015; 10(1): 187-200.
5. 5. Chen SC, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud, 2013; 10(2-3): 88-100.
6. 6. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol, 2002; 90(5A): 27-33.
7. 7. Dauchy RT, Blask DE, Sauer LA, Davidson LK, Krause JA, Smith LC, Dauchy EM. Physiologic melatonin concentration, omega-3 fatty acids, and conjugated linoleic acid inhibit fatty acid transport in rodent hind limb skeletal muscle in vivo. Comp Med, 2003; 53(2): 186-190.
8. 8. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000; 102: 42-47.

9. 9. Haddadi GH, Fardid R. Oral administration of melatonin modulates the expression of tumor necrosis factor-α (TNF-α) gene in irradiated rat cervical spinal cord. Rep Pract Oncol Radiother, 2015; 20(2): 123-127.
10. 10. Halse R, Pearson SL, McCormack JG, Yeaman SJ, Taylor R. Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes, 2001; 50(5): 1102-1109.
11. 11. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes, 1999; 107: 119-125.
12. 12. Hussain SA. Effect of melatonin on cholesterol absorption in rats. J Pineal Res, 2007; 42(3): 267-271.
13. 13. Jain SK, Rains JL, Croad JL. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. Free Radic Biol Med, 2007; 43(8): 1124-1131.
14. 14. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res, 2002; 36(12): 1331-1336.
15. 15. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis. Hypertension, 2004; 44(1): 6-11.
16. 16. Joo IIW, Ryu JH, Oh HJ. The Influence of Sam-Chil-Geun (Panax Notoginseng) on the Serum Lipid Levels and Inflammations of Rats with Hyperlipidemia Induced by Poloxamer-407. Yonsei Med J, 2010; 51(4): 504-510.
17. 17. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut, 1990; 31(7): 786-790.
18. 18. Kim JH, Hahm DH, Yang DC, Kim JH, Lee HJ, Shim I. Effect of Crude Saponin of Korean Red Ginseng on High-Fat Diet-Induced Obesity in the Rat. J Pharmacol Sci, 2005; 97(1): 124-131.
19. 19. Lee J, Lee HI, Seo KI, Cho HW, Kim MJ, Park EM, Lee MK. Effects of ursolic acid on glucose metabolism, the polyol pathway and dyslipidemia in non-obese type 2 diabetic mice. Indian J Exp Biol, 2014; 52(7): 683-691.
20. 20. Li GQ, Kam A, Wong KH, Zhou X, Omar EA, Alqahtani A, Li KM, Razmovski-Naumovski V, Chan K. Herbal medicines for the management of diabetes. Adv Exp Med Biol, 2012; 771: 396-413.
21. 21. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm, 2005; 2005(4): 185-193.
22. 22. Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T. Novel Adipocytokine, Visceral Adipose Tissue-derived Serine Protease Inhibitor (Vaspin), and Obesity. J Int Med Res, 2008; 36: 625-629.
23. 23. Libby P. Inflammation in atherosclerosis. Nature, 2002; 420: 868-874.
24. 24. Lo CC, Lin SH, Chang JS, Chien YW. Effects of melatonin on glucose homeostasis, antioxidant ability, and adipokine secretion in ICR mice with NA/STZ-induced hyperglycemia. Nutrients, 2017; 9(11): 1187.
25. 25. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses, 1999; 52: 465-477.
26. 26. Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hypertlipidemic individuals. Atherosclerosis, 2009; 204: 476-482.
27. 27. Mohammadi-Sartang M, Ghorbani M, Mazloom Z. Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr, 2018; 37(6 Pt A): 1943-1954.
28. 28. Montilla PL, Vargas JF, Tlinez IF, Muñoz de Agueda MC, Valdelvira ME, Cabrera ES. Oxidative stress in diabetic rats induced by streptozotocin: Protective effects of melatonin. J Pineal Res, 1998; 25(2): 94-100.
29. 29. Müller-wieland D, Behnke B, Koopmann K, Krone W. Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. Biochem Biophysical Res Commun, 1994; 203(1): 416-421.
30. 30. Nosalova V, Michal Z, Cerna S, Navarova J, Zakalova M. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res, 2007; 42(4): 364-370.
31. 31. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal?. FEBS J, 2006; 273(13): 2813-2838.
32. 32. Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem, 1998; 182(1-2): 169-175.
33. 33. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother, 2005; 59: 365-373.
34. 34. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses male rate visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology, 1999; 140(2): 1009-1012.
35. 35. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol, 2008; 79: 1544-1551.
36. 36. Rosenstock M, Greenberg AS, Rudich A. Distinct long-term regulation of glycerol and non-esterified fatty acid release by insulin and TNF-alpha in 3T3-L1 adipocytes. Diabetologia, 2001; 44(1): 55-62.
37. 37. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest, 2001; 107(2): 181-189.
38. 38. Sánchez A, Calpena AC, Clares B. Evaluating the oxidative stress in inflammation: role of melatonin. Int J Mol Sci, 2015; 16(8): 16981-17004.
39. 39. Sasaki M, Nishida N, Shimada M. A Beneficial Role of Rooibos in Diabetes Mellitus: A Systematic Review and Meta-Analysis. Molecules, 2018; 23(4): pii: E839.
40. 40. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med, 2003; 41(9): 1120-1130.
41. 41. Stanley S, Wynne K, Mcgowan B, Bloom S. Hormonal Regulation of Food Intake. Physiol Rev, 2005; 85: 1131-1158.
42. 42. Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol, 2011; 137(3): 1328-1333.
43. 43. Tahan G, Gramignoli R, Marongiu F, Aktolga S, Cetinkaya A, Tahan V, Dorko K. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci, 2011; 56(3): 715-720.
44. 44. Ugochukwu NH, Figgers CL. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpha, and activates IL-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats. J Nutr Biochem, 2007; 18(2): 120-126.
45. 45. Vicente R, Coma M, Busquets S, Moore-Carrasco R, López-Soriano FJ, Argilés JM, Felipe A. The systemic inflammatory response is involved in the regulation of K(+) channel expression in brain via TNF-alpha-dependent and -independent pathways. FEBS Lett, 2004; 572(1-3): 189-194.
46. 46. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest, 2005; 115(5): 1111-1119.
47. 47. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, Rasmussen DD. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology, 2000; 141(2): 487-497.
48. 48. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: Its etiology, effects and treatment. CMAJ, 2007; 176(8): 1113-1120.
49. 49. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol, 1999; 19(4): 972-978.